Adds details and background

Feb 6 (Reuters) - Shares of Agomab Therapeutics AGMB.O fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million.

The clinical-stage biopharmaceutical company's stock opened at $14.70, compared with the offer price of $16 apiece.

The company raised $200 million in its U.S. initial public offering on Thursday after it sold 12.5 million American Depositary Shares within its marketed range of $15 to $17 apiece.

A sharp sell-off in U.S. software and data-services stocks this week, driven by fears that rapidly advancing AI could upend existing business models, has made investors selective about new offerings.

Eikon Therapeutics EIKN.O fell on its debut on Thursday, while Liftoff Mobile postponed its planned U.S. listing amid a sell-off in software stocks.

Agomab is focused on developing treatments for immune and inflammatory diseases, starting with chronic fibrotic conditions.

J.P. Morgan, Morgan Stanley, Leerink Partners and Van Lanschot Kempen were underwriters for the offering.